Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
- PMID: 24834926
- PMCID: PMC4552899
- DOI: 10.1136/annrheumdis-2013-205171
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Abstract
Background and aims: We studied damage accrual and factors determining development and progression of damage in an international cohort of systemic lupus erythematosus (SLE) patients.
Methods: The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort recruited patients within 15 months of developing four or more 1997 American College of Rheumatology (ACR) criteria for SLE; the SLICC/ACR damage index (SDI) was measured annually. We assessed relative rates of transition using maximum likelihood estimation in a multistate model. The Kaplan-Meier method estimated the probabilities for time to first increase in SDI score and Cox regression analysis was used to assess mortality.
Results: We recruited 1722 patients; mean (SD) age 35.0 (13.4) years at cohort entry. Patients with damage at enrolment were more likely to have further worsening of SDI (SDI 0 vs ≥1; p<0.001). Age, USA African race/ethnicity, SLEDAI-2K score, steroid use and hypertension were associated with transition from no damage to damage, and increase(s) in pre-existing damage. Male gender (relative transition rates (95% CI) 1.48 (1.06 to 2.08)) and USA Caucasian race/ethnicity (1.63 (1.08 to 2.47)) were associated with SDI 0 to ≥1 transitions; Asian race/ethnicity patients had lower rates of new damage (0.60 (0.39 to 0.93)). Antimalarial use was associated with lower rates of increases in pre-existing damage (0.63 (0.44 to 0.89)). Damage was associated with future mortality (HR (95% CI) 1.46 (1.18 to 1.81) per SDI point).
Conclusions: Damage in SLE predicts future damage accrual and mortality. We identified several potentially modifiable risk factors for damage accrual; an integrated strategy to address these may improve long-term outcomes.
Keywords: Corticosteroids; Inflammation; Outcomes research; Systemic Lupus Erythematosus.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Figures


References
-
- Strand V, Gladman D, Isenberg D, et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490–7. - PubMed
-
- Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809–13. - PubMed
-
- Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373–6. - PubMed
-
- Sutton EJ, Davidson JE, Bruce IN. The Systemic Lupus International Collaborating Clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 2013;43:352–61. - PubMed
-
- Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93–6. - PubMed
Publication types
MeSH terms
Grants and funding
- P60 AR048095/AR/NIAMS NIH HHS/United States
- M01 RR000046/RR/NCRR NIH HHS/United States
- 1RR 025741/RR/NCRR NIH HHS/United States
- UL1 RR025741/RR/NCRR NIH HHS/United States
- UL1 TR001422/TR/NCATS NIH HHS/United States
- M01 RR000052/RR/NCRR NIH HHS/United States
- UL1 RR029882/RR/NCRR NIH HHS/United States
- R01 AR043727/AR/NIAMS NIH HHS/United States
- NF-SI-0512-10105/DH_/Department of Health/United Kingdom
- MANMKBRU-2012-1/DH_/Department of Health/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- UL1 TR001417/TR/NCATS NIH HHS/United States
- AR-43727/AR/NIAMS NIH HHS/United States
- P60-AR-48095/AR/NIAMS NIH HHS/United States
- P60 AR062755/AR/NIAMS NIH HHS/United States
- P60-AR-48098/AR/NIAMS NIH HHS/United States
- MOP-86526/CAPMC/ CIHR/Canada
- P60 AR064464/AR/NIAMS NIH HHS/United States
- P60 AR048098/AR/NIAMS NIH HHS/United States
- M01-RR-00052/RR/NCRR NIH HHS/United States
- U105261167/MRC_/Medical Research Council/United Kingdom
- MC_U105261167/MRC_/Medical Research Council/United Kingdom
- 20380/ARC_/Arthritis Research UK/United Kingdom
- RR00046/RR/NCRR NIH HHS/United States
- K24-AR-02318/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical